Expert Ratings for CME Group
Analysts have provided the following ratings for CME Group (NASDAQ:CME) within the last quarter:
Credit Suisse Maintains Neutral on CME Group, Lowers Price Target to $233
Credit Suisse analyst Gautam Sawant maintains CME Group (NASDAQ:CME) with a Neutral and lowers the price target from $242 to $233.
Raymond James Maintains Outperform on CME Group, Lowers Price Target to $235
Raymond James analyst Patrick O'Shaughnessy maintains CME Group (NASDAQ:CME) with a Outperform and lowers the price target from $254 to $235.
$100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today
CME Group (NASDAQ:CME) has outperformed the market over the past 10 years by 2.55% on an annualized basis producing an average annual return of 13.86%. Currently, CME Group has a market capitalization of $71.85 billion.
Atlantic Equities Upgrades CME Group to Overweight, Announces $235 Price Target
Atlantic Equities analyst Simon Clinch upgrades CME Group (NASDAQ:CME) from Neutral to Overweight and announces $235 price target.
Benzinga’s Top Ratings Upgrades, Downgrades For May 25, 2022
Upgrades
Credit Suisse upgraded the previous rating for Molecular Partners AG (NASDAQ:MOLN) from Underperform to Neutral. NoneAt the moment, the stock has a 52-week-high of $32.04 and a 52-week-low of $5.92. Molecular Partners closed at $6.88 at the end of the last trading period.
Oppenheimer Upgrades CME Group to Outperform, Announces $223 Price Target
Oppenheimer analyst Owen Lau upgrades CME Group (NASDAQ:CME) from Perform to Outperform and announces $223 price target.
Raymond James Maintains Outperform on CME Group, Lowers Price Target to $254
Raymond James analyst Patrick O'Shaughnessy maintains CME Group (NASDAQ:CME) with a Outperform and lowers the price target from $265 to $254.